Inhibitory effects of FUT-175, a new synthetic protease inhibitor, on intravascular hemolysis by human serum in mice

https://doi.org/10.1016/0192-0561(87)90120-2Get rights and content

Abstract

Effects of FUT-175, a new protease inhibitor, on intravascular hemolysis of mouse erythrocytes caused by intravenous injection of human serum was studied in mice. In in vitro experiments, unsensitized erythrocytes obtained from various species of animals were lysed with sera in EGTA-GVB-Mg++. After heat inactivation of sera at 50°C for 30 min, hemolysis in EGTA-GVB-Mg++ was abolished, indicating loss of activity of the alternative complement pathway. FUT-175 inhibited the alternative complement pathway-mediated hemolysis with IC50 values of 1.3 × 10−7 to 4.0 × 10−7M. Intravenous injection of human serum caused intravascular hemolysis of mouse erythrocytes in mice. No remarkable change was observed in the mice that were injected with heat-inactivated (56°C, 30 min) human serum. Intravenous administration of FUT-175 at a dose of 3 or 10 mg/kg inhibited intravascular hemolysis of mouse erythrocytes regardless of whether it was administered before or after injection of human serum. These results indicated that FUT-175 prevents intravascular hemolysis of mouse erythrocytes through the inhibitory effect of both alternative and classical complement pathway.

References (13)

  • T. Aoyama et al.

    Pharmacological studies of FUT-175, Nafamstat Mesilate

    Jap. J. Pharmac.

    (1984)
  • S. Fujii et al.

    New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin

    Biochim. biophys. Acta

    (1981)
  • K.D. Butler et al.

    Mechanisms of Forssman-induced bronchospasm and their inhibition

    Br. J. Pharmac.

    (1981)
  • C.G. Cochrane et al.

    Depletion of plasma complement in vivo by a protein of cobra venom : its effect on various immunologic reactions

    J. Immun.

    (1970)
  • Y. Hitomi et al.

    Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor

    Int. Archs Allergy appl. Immun.

    (1982)
  • N. Ikari et al.

    New synthetic inhibitor to the alternative complement pathway

    Immunology

    (1983)
There are more references available in the full text version of this article.

Cited by (8)

  • Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes

    2020, Blood Advances
    Citation Excerpt :

    In these mice, after NHS injection, mouse intravascular hemolysis mediated by activated human complement can be easily quantitated by measuring released hemoglobin in the plasma. Using this model, we and others demonstrated previously that complement inhibitors such as FUT-17513 and SSL-736 significantly reduced intravascular hemolysis, a common feature in patients with PNH, cold agglutinin disease, and aHUS. We found that when blood was collected 10 minutes after NHS injection to measure intravascular hemolysis, it showed that 1C9 administration significantly prevented or even abolished the human complement–mediated RBC destruction.

  • Near completely humanized liver in mice shows human-type metabolic responses to drugs

    2004, American Journal of Pathology
    Citation Excerpt :

    We investigated whether Futhan, by virtue of its activity as an inhibitor of human complement, was effective in yielding chimeric mice with high RI values. It was reported previously that mice showed hemolysis when they were injected intravascularly with human sera, whereas heat treatment of the sera abolished this effect.9 In addition, the administration of Futhan inhibited the serum-induced hemolysis.9

View all citing articles on Scopus
View full text